Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial
Ramez N. Eskander,Michael W. Sill,Lindsey Beffa,Richard G. Moore,Joanie Mayer Hope,Fernanda B. Musa,Robert S. Mannel,Mark S. Shahin,Guilherme Cantuaria,Eugenia Girda,Elizabeth Lokich,Juraj Kavecansky,Charles A. Leath,Lilian T. Gien,Emily Hinchcliff,Shashikant Lele,Lisa M. Landrum,Floor J. Backes,Roisin E. O’Cearbhaill,Tareq Al Baghdadi